ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Bausch + Lomb To Acquire ISTA In Cash Deal

DOW JONES NEWSWIRES Bausch + Lomb Monday agreed to acquire ISTA Pharmaceuticals Inc. (ISTA), swooping in with a higher offer for the eye-care company deal less than two months after a rival suitor withdrew its bid. ISTA shares jumped 7.8% to $9.03 after hours, slightly below Bausch + Lomb's $9.10 per-share offer price, which offers more than $380 million for Ista's outstanding shares. That values the company at a roughly 134% premium over its close Dec. 15, the day before ISTA confirmed its was weighing its strategic options. The latest offer comes after Valeant Pharmaceuticals International Inc. (VRX, VRX.T) withdrew a sweetened bid for the eye-care company. Valeant in January raised its offer for ISTA to $7.50 a share, with a target of $8.50 subject to due diligence. ISTA at the time said it would continue to review Valeant's offer, valued at up to $353 million, but said it would remain in talks with a number of parties that expressed interest in a strategic transaction. Basch + Lomb's deal, expected to close in the second quarter, won unanimous approval from both companies' boards. Basch + Lomb said the deal benefits from the two companies' complementary development pipelines. The companies plan to continue operating independently until the deal closes. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; Andrew.FitzGerald@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
05/31/201618:00:00Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016
05/31/201618:00:00Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016
05/31/201617:15:46Specialized Disclosure Report (sd)
05/31/201608:48:14Current Report Filing (8-k)
05/27/201611:46:00Correction to Valeant CEO Article on April 21
05/26/201621:00:00Valeant Rejected Joint Takeover Approach From Takeda, TPG
05/26/201607:00:00Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President...
05/26/201607:00:00Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President...
05/25/201613:00:00Pharming Reports on Annual General Meeting of Shareholders Pharming's...
05/24/201618:28:00SEC Reviewed Valeant's Use of 'Non-GAAP' Financial Measures...
05/24/201617:09:13Additional Proxy Soliciting Materials (definitive) (defa14a)
05/24/201614:30:00SEC Reviewing Valeant's Use of 'Non-GAAP' Financial Measures
05/24/201614:22:00SEC Reviewing Valeant's Use of 'Non-GAAP' Financial Measures
05/23/201607:00:00Bausch + Lomb Wins Walmart "Supplier of the Year" Award
05/23/201607:00:00Bausch + Lomb Wins Walmart "Supplier of the Year" Award
05/20/201618:20:00Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock
05/20/201616:20:26Current Report Filing (8-k)
05/20/201606:07:08Current Report Filing (8-k)
05/19/201618:00:00Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
05/19/201618:00:00Valeant Pharmaceuticals Receives Notice Of Default From Bondholders

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad